TFF Pharmaceuticals Inc. closed a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.
TFF Pharmaceuticals Inc. closed a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.
03/26/24, 3:34 PM
Location
fort worthMoney raised
$1.2 million
Round Type
seed
Investors
H.C. Wainwright & Co.
TFF Pharmaceuticals, Inc announced the closing of a registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share. The gross proceeds to the company from the offering were approximately $1.2 million, with the net proceeds intended for working capital and general corporate purposes.
Company Info
Location
2600 via fortuna
fort worth, texas, united states
Additional Info
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.